6 January 2026 in Journal of the American Heart Association
Background: The inactivating ALDH2 rs671 polymorphism, present in ≈8% of the global population and up to 30% to 50% of East Asian individuals, has been negatively associated with hypertension. However, the direct role of ALDH2 (aldehyde dehydrogenase 2) dysfunction in this association, as well as the underlying mechanisms by which ALDH2 rs671 influences blood pressure regulation, remains unclear. Methods: Using Aldh2 E506K (equivalent to the human ALDH2 rs671 polymorphism), Aldh2 global knockout, and endothelial cell‐specific Aldh2 knockout mice, we assessed changes in blood pressure (BP) using both telemetry and tail‐cuff methods. Mass spectrometry, coimmunoprecipitation, and other biological techniques were used to elucidate underlying molecular mechanisms. Results: Aldh2 E506K or Aldh2 global knockout mice displayed a significant decrease in BP under both physiological conditions and angiotensin II–induced hypertension, independent of changes in cardiac output and renal function. Mechanistic studies revealed that endothelial ALDH2 dysfunction inhibited the lysosomal degradation of PIEZO1 (piezo‐type mechanosensitive ion channel component 1), resulting in its upregulated protein level and activation of the PIEZO1–endothelial nitric oxide synthase BP regulatory axis. PIEZO1 knockdown or channel inhibition by Grammostola spatulata mechanotoxin 4 peptide reversed the reduced BP phenotype exhibited by Aldh2 ECKO mice. Using coimmunoprecipitation combined with mass spectrometry, the molecular chaperone HSPA5 (heat shock protein family A member 5) was identified as a novel interactor with PIEZO1, binding to its C‐terminus. HSPA5, induced by aldehyde accumulation, functionally enhanced PIEZO1 protein stability upon ALDH2 loss‐of‐function mutation. Endothelial‐specific overexpression of HSPA5 could alleviate angiotensin II–induced hypertension in mice. Conclusions: Our study provides definitive experimental evidence that ALDH2 rs671 variation or endothelial Aldh2 deficiency plays a protective role in BP regulation by activating the HSPA5–PIEZO1–endothelial nitric oxide synthase axis. We also revealed the previously unrecognized role of HSPA5 in maintaining PIEZO1 stability and BP regulation, providing a potential novel intervention target for hypertension therapy.
14 November 2025 in Science Advances
As a mechanosensitive channel, PIEZO1 translates mechanical stretching of cardiomyocytes into Ca 2+ signaling, underpinning the Frank-Starling law. This mechanism contributes to compensatory responses in heart failure. However, the relationship between PIEZO1 mutations and the development of cardiomyopathy remains unclear. Acute heart failure complicated with severe myocardial iron deposition was identified in the 31-year-old male proband of PIEZO1 D669Y variant. However, PIEZO1 gain-of-function (GOF) mutation D674Y mice and cardiomyocyte-specific Piezo1 overexpression disrupted cardiac function besides iron overload. Using single-cell RNA sequencing, we observed suppression of lipid metabolism pathways in cardiomyocytes with the PIEZO1 GOF mutation, with forkhead box O3 (FOXO3) as a key mediator in lipid metabolism pathways. Specifically, the PIEZO1 GOF mutation increased Ca 2+ levels, leading to calcium- and calmodulin-dependent protein kinase II (CaMKII) activation and subsequent FOXO3 down-regulation. Together, we demonstrate that PIEZO1 GOF mutation contributes to cardiomyopathy by disrupting myocardial lipid metabolism. This study challenges the current clinical focus on iron-related mechanisms in cardiomyopathy and supports PIEZO1 as a potential candidate for future genetic screening for cardiomyopathy.